The mutational landscape in the ET group is heterogeneous combining JAK2-, CALR-, MPL-mutated, and triple-negative patients possibly leading to a bias in the gene expression patterns between the different subtypes. The gene discussed is MPL; the disease is essential thrombocythemia.